Royalty Pharma
RPRX
RPRX
235 hedge funds and large institutions have $10.3B invested in Royalty Pharma in 2021 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
5% less capital invested
Capital invested by funds: $10.8B → $10.3B (-$488M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
28% less call options, than puts
Call options by funds: $34.6M | Put options by funds: $48M
Holders
235
Holding in Top 10
9
Calls
$34.6M
Puts
$48M
Top Buyers
| 1 | +$110M | |
| 2 | +$103M | |
| 3 | +$76.1M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$75M |
| 5 |
JPMorgan Chase & Co
New York
|
+$62.3M |
Top Sellers
| 1 | -$158M | |
| 2 | -$146M | |
| 3 | -$138M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$80.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$79.3M |